33 / 74 · 0:51 · Original AXON film
Cartalax
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Cartalax | Check the study material
Cartalax, also spelled Kartalax, is linked in the literature to the tripeptide AED. Evaluating joint-repair claims starts with identifying the actual study material. [2]
RAT CELLS | Skin fibroblasts
One primary experiment studied AED in aging rat skin-fibroblast cultures. Researchers measured proteins involved in cell growth, cell death and extracellular-matrix remodeling. [1]
REVIEW | Trace the underlying evidence
A later review discusses cartilage biology and reports broader animal and patient claims. A review summary alone does not verify a controlled trial of a defined product. [2]
Joint-regrowth claims are not established
These sources do not establish that Cartalax rebuilds human joints. The exact formulation, clinical methods, meaningful outcomes and safety evidence need to be checked. [1] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Lin’kova et al. (2016): Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro →AED experiments in rat skin fibroblast cultures, not a cartilage-repair patient trial.
- Myakisheva et al. (2023): Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation →Maps Kartalax to AED and reports broader claims whose primary clinical methods were not independently verified.
